公开(公告)号：EP1824820A2

公开(公告)日：2007-08-29

申请号：EP05815588.8

申请日：2005-12-06

申请人： JANSSEN PHARMACEUTICA N.V.

发明人： CID-NUÑEZ, José M., Johnson & Johnson Pharmaceut ,  MEGENS, Antonius Adrianus Hendrikus Petrus ,  TRABANCO-SUÁREZ, A. A., Johnson & Johnson Pharm. ,  KOUKNI, Mohamed ,  HOORNAERT, Georges Joseph, Cornelius K.U. Leuven Research & ,  COMPERNOLLE, Frans Josef, Cornelius K.U. Leuven Research & ,  KOZLECKI, Tomasz ,  MAO, Hua ,  JHA, Sushil Chandra ,  FERNÁNDEZ-GADEA, Francisco Javier

IPC分类号： C07D209/70 ,  C07D221/18 ,  C07D307/93 ,  C07D311/94 ,  C07D333/80 ,  C07D487/04 ,  C07D491/044 ,  A61K31/343 ,  A61K31/352 ,  A61K31/381 ,  A61K31/403 ,  A61K31/407 ,  A61K31/496 ,  A61K31/4188 ,  A61K31/4985 ,  A61K31/5377 ,  A61P25/00

CPC分类号： C07D333/80 ,  C07D209/70 ,  C07D221/18 ,  C07D307/93 ,  C07D311/94 ,  C07D487/04 ,  C07D491/04

摘要： This invention concerns novel substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives with binding affinities towards serotonin receptors, in particular 5-HT2A and 5-HT2C receptors, and towards dopamine receptors, in particular dopamine D2 receptors and with norepinephrine reuptake inhibition properties, pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1.